Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of JNJ-54175446 in Healthy Subjects
NCT02475148Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-54175446 in major depressive disorder (MDD) (8 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events up to 21 days, Maximum Tolerated Dose of JNJ-54175446 in Part 1 at 24 hours and 10 more. Started Jun 2015; status: completed.
02
Drugs
JNJ-54175446
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02475148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475148.